Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Agilent Technologies    A


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Agilent Technologies : Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC; PD-L1 IHC 22C3 pharmDx Can Now Be Used to Identify a Broader Range of NSCLC Patients for First-line Treatment With KEYTRUDA® (pembrolizumab)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/17/2019 | 04:29am EDT

SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has updated its approval of the company's PD-L1 IHC 22C3 pharmDx assay.

The assay can now be used as a companion diagnostic to identify a broader range of patients with stage III or metastatic non-small cell lung cancer (NSCLC) for first-line treatment with KEYTRUDA, a targeted anti-PD-1 therapy manufactured by Merck & Co. (known as MSD outside the United States and Canada).

The FDA previously approved the assay to identify metastatic NSCLC patients whose tumors express PD-L1 Tumor Proportion Score (TPS) >= 50% for first-line treatment with KEYTRUDA. Now, patients with stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 TPS >= 1% are eligible for first-line treatment. This expanded indication enables pathologists to identify a larger population of previously untreated patients who are now eligible for treatment with KEYTRUDA.

"Anti-PD-1 therapies are a promising treatment class for many cancer types, and PD-L1 testing provides key information to physicians managing stage III or metastatic NSCLC patients," said Sam Raha, president of Agilent's Diagnostics and Genomics Group. "The updated FDA approval of PD-L1 IHC 22C3 pharmDx broadens the scope of patients that can be identified for first-line treatment with KEYTRUDA and offers new hope to the many patients diagnosed with stage III or metastatic NSCLC. By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to continue our legacy of pioneering companion diagnostics to support the launch of landmark therapies."

Lung cancer is the leading cause of cancer-related mortality in the United States, with an estimated incidence of 154,000 deaths in 2018 alone.1 Among these cases, NSCLC accounts for nearly 85% of all diagnoses, and carries a 5-year survival rate of 15%.2 PD-L1 is a critical biomarker for response to anti-PD-1 therapy, and pathology labs play an important role in identifying appropriate patients for these treatments.

Agilent's PD-L1 IHC 22C3 pharmDx is the first and only companion diagnostic that has been clinically validated and approved to identify NSCLC patients eligible for KEYTRUDA.

KEYTRUDA is a humanized monoclonal antibody that increases the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells. KEYTRUDA and other targeted immunotherapies are revolutionizing cancer treatment, and their therapeutic value is being demonstrated across a growing list of cancer types.

Agilent is a worldwide leader in partnering with pharmaceutical companies to develop immunohistochemical-based diagnostics for cancer therapy. Agilent developed PD-L1 IHC 22C3 pharmDx in partnership with Merck & Co. PD-L1 IHC 22C3 pharmDx also helps physicians identify cervical cancer, gastric or GEJ adenocarcinoma, and urothelial carcinoma patients for treatment with KEYTRUDA. PD-L1 expression in NSCLC tissues is interpreted using Tumor Proportion Score (TPS). PD-L1 expression in urothelial carcinoma, cervical cancer, and gastric or GEJ adenocarcinoma tissues is interpreted using Combined Positive Score (CPS). About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on Linked In, Twitter, and Facebook.


1 Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. National Cancer Institute. https://seer.cancer.gov/csr/1975_2015/. November 2017 SEER data submission. Published April 2018. Accessed September 21, 2018.

2 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-594.


(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
AGILENT TECHNOLOGIES -0.01% 75.56 Delayed Quote.12.02%
MERCK AND COMPANY 1.55% 74.6 Delayed Quote.-2.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
04/17AGILENT TECHNOLOGIES : Receives an Expanded FDA Approval for its Companion Diagn..
04/16AGILENT TECHNOLOGIES : Receives an Expanded FDA Approval for its Companion Diagn..
04/16AGILENT TECHNOLOGIES : ACEA Biosciences – A Part of Agilent Launches the x..
04/16AGILENT TECHNOLOGIES : to Host Webcast of Second-Quarter Fiscal Year 2019 Financ..
04/15AGILENT TECHNOLOGIES : Introduces New Mass Spectrometry Solutions; Increased cap..
04/15AGILENT TECHNOLOGIES : Presents Thought Leader Award to Professor Antoni Ribas
04/15AGILENT TECHNOLOGIES : Introduces New Mass Spectrometry Solutions
04/12AGILENT TECHNOLOGIES : Presents Thought Leader Award to Professor Antoni Ribas
04/03AGILENT TECHNOLOGIES : Introduces New System for RNA and DNA Quality Control Lab..
04/02AGILENT TECHNOLOGIES : Introduces New System for RNA and DNA Quality Control Lab..
More news
Financials ($)
Sales 2019 5 187 M
EBIT 2019 1 201 M
Net income 2019 1 161 M
Finance 2019 1 062 M
Yield 2019 0,87%
P/E ratio 2019 21,34
P/E ratio 2020 24,48
EV / Sales 2019 4,42x
EV / Sales 2020 4,08x
Capitalization 23 991 M
Duration : Period :
Agilent Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGILENT TECHNOLOGIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 88,4 $
Spread / Average Target 17%
EPS Revisions
Michael R. McMullen President, Chief Executive Officer & Director
Boon Hwee Koh Non-Executive Chairman
Kristin Giffin Vice President-Operations, Quality & Support
Robert W. McMahon Chief Financial Officer & Senior Vice President
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA7.38%47 313